CDK4 and neutropenia: Among the 2218 patients included in the analysis, 70 patients (3.2 %) developed severe neutropenia, defined as an absolute neutrophil count (ANC) of less than 0.5 × 10^9/L, during the first three months of CDK4/6 inhibitor therapy.